Form 4: West Pharmaceutical Services Director Receives Phantom Stock Unit Award

Janet Haugen, a Director at West Pharmaceutical Services Inc., was awarded 58 phantom stock units on June 30, 2025, as part of her compensation package.

Summary

• Janet Haugen, a Director of West Pharmaceutical Services Inc. (WST), was awarded 58 phantom stock units.
• The transaction date for this award was June 30, 2025.
• Each phantom stock unit was valued at $218.8.
• These phantom stock units are designated to be settled by the delivery of shares of common stock upon Ms. Haugen's termination as a director.
• Following this transaction, Ms. Haugen directly beneficially owns 114.06 phantom stock units and 1,318.4 shares of common stock.

Sentiment

Score: 6

Explanation: The transaction is a routine compensation award, which is generally positive for aligning director interests with shareholders, but does not indicate significant new positive or negative developments for the company's operational or financial performance.

Positives

• The award of phantom stock units aligns the director's interests with those of shareholders, as the value of the units is tied to the company's stock performance.
• This form of equity compensation can contribute to director retention and long-term commitment.

Negatives

• The future settlement of phantom stock units into common stock could result in minor dilution for existing shareholders, although the quantity in this instance is small.

Future Outlook

The phantom stock units are structured to be settled by the delivery of shares of stock upon the reporting person's termination as a director, indicating a long-term incentive and retention mechanism.

Industry Context

This transaction represents a routine equity compensation award to a director, which is a common practice across various industries to align executive and board member interests with shareholder value and long-term company performance.

Comparison to Industry Standards

• The award of phantom stock units is a standard form of equity compensation for directors in publicly traded companies, comparable to practices observed in other healthcare and pharmaceutical services firms.
• Specific comparable companies, projects, or detailed results are not provided in this filing, as its focus is on an individual's transaction rather than broader industry performance metrics.

Related Party Transactions

• The award of 58 phantom stock units to Janet Haugen, a Director of West Pharmaceutical Services Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The award of phantom stock units aligns the director's interests with shareholders, potentially fostering better long-term decision-making. However, future settlement could result in minor share dilution.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Settlement of phantom stock units by delivery of shares upon the reporting person's termination as a director.

Key Dates

Keywords

West Pharmaceutical Services, WST, SEC Form 4, Phantom Stock Units, Director Compensation, Equity Award, Insider Transaction, Janet Haugen